Biomark HD overview
The flexible Biomark system provides scalable performance to meet the complex needs of the molecular research laboratory. Achieve new economies of scale across multiple applications, all on the same system:
- qPCR for gene and miRNA expression
- Copy number variation
- Digital PCR
Tumor gene expression has proven effective in measuring immune response during cancer progression and therapeutic response. As emerging therapies reveal new biomarkers and expand the need for samples, the costs and labor required to complete this important work also rise. Cancer researchers now have a reliable, sensitive and cost-effective tool for identifying gene expression signatures from immune and cancer cells: the new Advanta™ Immuno-Oncology Gene Expression Assay, used with the Biomark™ HD system.
A powerful immuno-oncology focused assay
The Advanta Immuno-Oncology Gene Expression Assay was developed in collaboration with leading academic and biopharma researchers to provide the right balance of biomarker breadth, assay flexibility and workflow efficiency.
The panel consists of 170 genes, including 91 reported in Nature, where Roy Herbst et al. defined a gene set representing tumor and immune response. The panel includes markers for:
- Immune cell identification
- Immune and cancer cell function
- Immune regulation and cell fate
- Checkpoint therapy response
Optimized for FFPE and fresh frozen tumor samples, the Advanta Immuno-Oncology Gene Expression Assay uses TaqMan® chemistry to sensitively measure gene expression, with five reference genes serving as analysis controls. Combined with Fluidigm microfluidics technology, the assay uniquely offers significant workflow efficiencies over traditional gene expression profiling methods. Each reaction is miniaturized to nanoliter volume and controlled using precise automation to empower accurate and cost-effective qPCR analysis across a large dynamic range. Since assay introduction into the integrated fluidic circuit (IFC) is under user control, researchers also have the flexibility to add up to 17 new assays or exchange gene assays within the panel to achieve experimental goals—all without affecting the original panel content, protocol or workflow.
Immuno-Oncology Expression Assay
|Panel A||Panel B|
|CD8A||IL10||PDCD1 (PD-1)||Housekeeping genes for panels A and B:
B2M, ACTB, GUSB, TFRC
Table 1. The Advanta Immuno-Oncology Gene Expression Assay panels A and B. This two-panel set includes 91 target genes and 5 housekeeping genes on Panel A and 74 target genes and the same 5 housekeeping genes on Panel B. Panel B reserves 17 open assay inlets, so you have the added flexiblity to add new assays over time for customization. Each panel is available in packs of 2 or 10 (192 or 960 samples, respectively)
Sample case study
In a 2016 paper published by The Lancet for the POPLAR study, “Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer,” Louis Fehrenbacher et al. detailed how they “assessed efficacy and safety of atezolizumab versus docetaxel in previously treated NSCLC, analyzed by PD-L1 expression levels on tumor cells and tumor-infiltrating immune cells and in the intention-to-treat population.” The team showed that “patients with pre-existing immunity, defined by high T-effector–interferon-γ-associated gene expression, had improved overall survival with atezolizumab.”
Fehrenbacher’s group noted that atezolizumab “significantly improved survival compared with docetaxel in patients with previously treated NSCLC. Improvement correlated with PD-L1 immunohistochemistry expression on tumor ce/p>lls and tumor-infiltrating immune cells,” leading them to conclude: “PD-L1 expression is predictive for atezolizumab benefit. Atezolizumab was well tolerated, with a safety profile distinct from chemotherapy.”
The researchers performed the clinical trial using immunohistochemistry, and also ran a gene expression panel of 91 genes featured in the Herbst paper. These genes are included in the Advanta Immuno-Oncology Gene Expression Assay. The team subsequently used these results to develop a gene signature based on a subset of the panel, effectively predicting therapeutic response that provides data that could potentially be used for developing future diagnostics tests.
Achieve greater overall productivity
The Advanta Immuno-Oncology Gene Expression Assay is optimized to run on the industry-proven Biomark HD system. This automated system enables researchers to easily run up to 96 samples at once with limited hands-on time, while delivering trusted performance. Together with the capability to sensitively detect biomarkers across defined T cell subsets, immune regulation, immune cell fate, cytokines, chemokines and more with exceptional cost-efficiency, this new assay offers an ideal solution to meet the rigorous demands of translational research studies.
Advanta IO Gene Expression Assay ordering information
|Product Name||Contents||Part Number|
|Advanta Immuno-Oncology Gene Expression Assay Panel A-2 IFCs||Reagents, assay, syringes, IFCs||101-6082|
|Advanta Immuno-Oncology Gene Expression Assay Panel B-2 IFCs||Reagents, assay, syringes, IFCs||101-6083|
|Advanta Immuno-Oncology Gene Expression Assay Panel A & B-4 IFCs||Reagents, assay, syringes, IFCs||101-6084|
|Advanta Immuno-Oncology Gene Expression Assay Panel A-10 IFCs||Reagents, assay, syringes, IFCs||101-6086|
|Advanta Immuno-Oncology Gene Expression Assay Panel B-10 IFCs||Reagents, assay, syringes, IFCs||101-6087|
|Advanta Immuno-Oncology Gene Expression Assay Panel A & B-20 IFCs||Reagents, assay, syringes, IFCs||101-6088|
Contact us to learn more about the Biomark HD system and the Advanta Immuno-Oncology Gene Expression Assay.
For Research Use Only. Not for use in diagnostic procedures.